- Home
- WHWK vs CRBU Comparison
WHWK vs CRBU Comparison
Compare WHWK & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WHWK | CRBU |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | 22 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.8M | 203.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | WHWK | CRBU |
|---|---|---|
| Price | $3.46 | $1.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $10.75 |
| AVG Volume (30 Days) | 160.4K | ★ 1.2M |
| Earning Date | 03-12-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.63 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.39 | $0.66 |
| 52 Week High | $4.40 | $3.53 |
Technical Indicators
Market Signals| Indicator | WHWK | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 50.41 | 51.56 |
| Support Level | $1.84 | $1.70 |
| Resistance Level | $3.77 | $2.07 |
| Average True Range (ATR) | 0.28 | 0.12 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 34.85 | 52.44 |
Price Performance
Historical ComparisonAbout WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.